How Does Multiple Sclerosis Affect Patients' Quality of Life?

Article

Patients with multiple sclerosis (MS) commonly experience tremoring limbs, head pain, and blurred vision, among other symptoms. Fatigue is another commonly reported and has the power to alter a patient's quality of life (QoL). But by how much?

Patients with multiple sclerosis (MS) commonly experience tremoring limbs, head pain, and blurred vision, among other symptoms. Fatigue is another commonly reported and has the power to alter a patient’s quality of life (QoL). But by how much?

In a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain, Arzu Ozdincler, a professor at Istanbul University, and colleagues will weigh in on their recent findings on the matter.

The team analyzed 104 patients with MS (78 females and 26 males) and an average age around 41. Of those, 76 had a relapsing-remitting type of MS and 28 had a progressive type. The average Expanded Disability Status Scale (EDSS) score was 4.31±1.37.

To evaluate the QoL, the researchers used the Fatigue Severity Scale (FSS), Berg Balance Scale (BBS), and Multiple Sclerosis International Quality of Life (MusiQoL). Average scores were as follows:

  • FSS (fatigue level): 40.14±8.75
  • BBS (balance level): 38.03±10.99
  • MusiQoL (health-related QoL): 63.53±13.70

“There was a significant correlation between fatigue level and QoL (r=0.581 p=0.023), but there was not any correlation between fatigue level-balance (r=0.086 p=0.383) and balance-QoL (r=0.242 p=0.384),” the researchers confirmed.

The findings determined that fatigue has a strong influence on the QoL of patients with MS. This indicates that fatigue is a crucial symptom to tackle in treatment.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.